224 related articles for article (PubMed ID: 21134286)
21. A noble function of BAY 11-7082: Inhibition of platelet aggregation mediated by an elevated cAMP-induced VASP, and decreased ERK2/JNK1 phosphorylations.
Lee HS; Kim SD; Lee WM; Endale M; Kamruzzaman SM; Oh WJ; Cho JY; Kim SK; Cho HJ; Park HJ; Rhee MH
Eur J Pharmacol; 2010 Feb; 627(1-3):85-91. PubMed ID: 19913011
[TBL] [Abstract][Full Text] [Related]
22. [Effect of benzo(a)pyrene on platelet aggregation and expression of P-selectin].
Tang Q; Wu YH; Li F; Yang J
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2011 Jan; 40(1):51-6. PubMed ID: 21319374
[TBL] [Abstract][Full Text] [Related]
23. Platelet activation patterns in platelet size sub-populations: differential responses to aspirin in vitro.
Mangalpally KK; Siqueiros-Garcia A; Vaduganathan M; Dong JF; Kleiman NS; Guthikonda S
J Thromb Thrombolysis; 2010 Oct; 30(3):251-62. PubMed ID: 20502945
[TBL] [Abstract][Full Text] [Related]
24. Platelet alpha-granule secretion and its modification by SC-57101A, a GPIIb/IIIa antagonist.
Ogawa T; Sugidachi A; Otsuguro K; Isobe T; Asai F
Biochem Pharmacol; 2002 May; 63(10):1911-8. PubMed ID: 12034376
[TBL] [Abstract][Full Text] [Related]
25. LDL oxidized by hypochlorous acid causes irreversible platelet aggregation when combined with low levels of ADP, thrombin, epinephrine, or macrophage-derived chemokine (CCL22).
Coleman LG; Polanowska-Grabowska RK; Marcinkiewicz M; Gear AR
Blood; 2004 Jul; 104(2):380-9. PubMed ID: 15054038
[TBL] [Abstract][Full Text] [Related]
26. Full activation of mouse platelets requires ADP secretion regulated by SERCA3 ATPase-dependent calcium stores.
Elaïb Z; Adam F; Berrou E; Bordet JC; Prévost N; Bobe R; Bryckaert M; Rosa JP
Blood; 2016 Aug; 128(8):1129-38. PubMed ID: 27301859
[TBL] [Abstract][Full Text] [Related]
27. The role of PGE(2) in human atherosclerotic plaque on platelet EP(3) and EP(4) receptor activation and platelet function in whole blood.
Schober LJ; Khandoga AL; Dwivedi S; Penz SM; Maruyama T; Brandl R; Siess W
J Thromb Thrombolysis; 2011 Aug; 32(2):158-66. PubMed ID: 21424266
[TBL] [Abstract][Full Text] [Related]
28. The in-vitro effect of tirofiban, glycoprotein IIb/IIIa antagonist, on various responses of porcine blood platelets.
Ciborowski M; Tomasiak M; Rusak T; Winnicka K; Dobrzycki S
Blood Coagul Fibrinolysis; 2008 Sep; 19(6):557-67. PubMed ID: 18685439
[TBL] [Abstract][Full Text] [Related]
29. Abciximab treatment in vitro after aspirin treatment in vivo has additive effects on platelet aggregation, ATP release, and P-selectin expression.
Scazziota A; Altman R; Rouvier J; Gonzalez C; Ahmed Z; Jeske WP; Walenga JM; Fareed J
Thromb Res; 2000 Dec; 100(6):479-88. PubMed ID: 11152927
[TBL] [Abstract][Full Text] [Related]
30. Halysin, an antiplatelet Arg-Gly-Asp-containing snake venom peptide, as fibrinogen receptor antagonist.
Huang TF; Liu CZ; Ouyang CH; Teng CM
Biochem Pharmacol; 1991 Aug; 42(6):1209-19. PubMed ID: 1888330
[TBL] [Abstract][Full Text] [Related]
31. The catalytic subunit of protein phosphatase 1 gamma regulates thrombin-induced murine platelet alpha(IIb)beta(3) function.
Gushiken FC; Hyojeong H; Pradhan S; Langlois KW; Alrehani N; Cruz MA; Rumbaut RE; Vijayan KV
PLoS One; 2009 Dec; 4(12):e8304. PubMed ID: 20016849
[TBL] [Abstract][Full Text] [Related]
32. Licofelone, an inhibitor of cyclooxygenase and 5-lipoxygenase, specifically inhibits cyclooxygenase-1-dependent platelet activation.
Rotondo S; Krauze-Brzósko K; Manarini S; Evangelista V; Cerletti C
Eur J Pharmacol; 2004 Mar; 488(1-3):79-83. PubMed ID: 15044038
[TBL] [Abstract][Full Text] [Related]
33. Enhancement of human platelet aggregation and secretion induced by rapamycin.
Babinska A; Markell MS; Salifu MO; Akoad M; Ehrlich YH; Kornecki E
Nephrol Dial Transplant; 1998 Dec; 13(12):3153-9. PubMed ID: 9870481
[TBL] [Abstract][Full Text] [Related]
34. Biological properties of a specific Galpha q/11 inhibitor, YM-254890, on platelet functions and thrombus formation under high-shear stress.
Uemura T; Kawasaki T; Taniguchi M; Moritani Y; Hayashi K; Saito T; Takasaki J; Uchida W; Miyata K
Br J Pharmacol; 2006 May; 148(1):61-9. PubMed ID: 16520742
[TBL] [Abstract][Full Text] [Related]
35. Parnaparin, a low-molecular-weight heparin, prevents P-selectin-dependent formation of platelet-leukocyte aggregates in human whole blood.
Maugeri N; Di Fabio G; Barbanti M; de Gaetano G; Donati MB; Cerletti C
Thromb Haemost; 2007 Jun; 97(6):965-73. PubMed ID: 17549299
[TBL] [Abstract][Full Text] [Related]
36. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors.
Gawaz M; Ruf A; Pogatsa-Murray G; Dickfeld T; Rüdiger S; Taubitz W; Fischer J; Müller I; Meier D; Patscheke H; Schömig A
Thromb Haemost; 2000 Jun; 83(6):915-22. PubMed ID: 10896249
[TBL] [Abstract][Full Text] [Related]
37. Regulation of human platelet activation--analysis of cyclooxygenase and cyclic AMP-dependent pathways.
Krishnamurthi S; Westwick J; Kakkar VV
Biochem Pharmacol; 1984 Oct; 33(19):3025-35. PubMed ID: 6091666
[TBL] [Abstract][Full Text] [Related]
38. ATP-secretion occurs as an initial response in collagen induced platelet activation.
Malmgren R
Thromb Res; 1986 Aug; 43(4):445-53. PubMed ID: 3094190
[TBL] [Abstract][Full Text] [Related]
39. ATP augments von Willebrand factor-dependent shear-induced platelet aggregation through Ca2+-calmodulin and myosin light chain kinase activation.
Oury C; Sticker E; Cornelissen H; De Vos R; Vermylen J; Hoylaerts MF
J Biol Chem; 2004 Jun; 279(25):26266-73. PubMed ID: 15087444
[TBL] [Abstract][Full Text] [Related]
40. Development of Benzimidazole Derivatives as Novel Anti-platelet Drugs.
Yao W-C; Yuan L-T; Yang W-B; Hsia C-H; Huang L-T; Lee T-Y; Sheu J-R; Lu W-J; Jayakumar T; Chen R-J
Curr Pharm Biotechnol; 2017; 18(7):594-605. PubMed ID: 28828982
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
